Table 3.

Potential metabolites of gefitinib, losartan, and SSRIs: citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, and venlafaxine from hepatocytes and CYP1A2, 2C9, 2C19, 2D6, and 3A4 screening. Observed potential metabolite is recorded as “+“. Potential metabolites were previously described for gefitinib (McKillop et al., 2004, 2005), losartan (Sica et al., 2005), citalopram (Sangkuhl et al., 2011), fluoxetine (Deodhar et al., 2021), fluvoxamine (van Harten, 1995), sertraline (Obach et al., 2005; DeVane et al., 2002), and venlafaxine (Sangkuhl et al., 2014).

Parent Drugs	Metabolites Information	Potential Metabolite	Hepatocytes	CYP 1A2	CYP 2C9	CYP 2C19	CYP 2D6	CYP 3A4
Gefitinib (m/z-447)	Demethylation	m/z-433	+		+		+	+
	Dehydrogenation	m/z-445	+					+
	(+25 amu)	m/z-472	+	+	+	+		+
Losartan (m/z-423)	N-Oxidation	m/z-439	+		+			+
Citalopram (m/z-325)	Demethylation	m/z-311	+		+	+	+	+
	N- Methylation	m/z-338	+			+	+
	N-Oxidation	m/z-341	+		+	+	+	+
	(+27 amu)	m/z-352	+		+	+	+	+
Fluoxetine (m/z-310)	Demethylation	m/z-296	+				+
	(+27 amu)	m/z-337	+		+	+	+
Fluvoxamine (m/z-319)	Demethylation	m/z-305	+				+
	(+27 amu)	m/z-346	+				+
Sertraline (m/z-306)	Demethylation	m/z-292	+	+	+	+	+	+
	(+27 amu)	m/z-333	+	+	+	+	+	+
Venlafaxine (m/z-278)	Demethylation	m/z-264	+			+	+
	(+27 amu)	m/z-305	+			+